Table 3.
The clinic-pathological parameters among patients with different treatment response and toxicity
| Characteristic | Response to chemotherapy(N = 90) | Toxicity to chemotherapy(N = 211) | ||||
|---|---|---|---|---|---|---|
| Response (N = 29) | Non-response (N = 61) | p | Toxicity (N = 102) | No toxicity (N = 109) | P | |
| Age in years(mean ± SD) | 0.539 | 0.195 | ||||
| ≤ 45 | 4(13.8) | 10(16.4) | 17(16.7) | 22(20.2) | ||
| 46–55 | 10(34.5) | 27(44.3) | 39(38.2) | 29(26.6) | ||
| > 55 | 15(51.7) | 24(39.3) | 46(45.1) | 58(53.2) | ||
| Menstrual status | 0.516 | 0.891 | ||||
| Premenopausal | 8(27.6) | 21(34.4) | 30(29.4) | 33(30.3) | ||
| Postmenopausal | 21(72.4) | 40(65.6) | 72(70.6) | 76(69.7) | ||
| T-status,n(%) | 0.250 | <0.001* | ||||
| T1 | / | / | / | / | ||
| T2 | 1(3.4) | 5(8.2) | 17(16.7) | 74(67.9) | ||
| T3 | 27(93.1) | 56(91.8) | 84(82.4) | 32(29.4) | ||
| T4 | 1(3.4) | 0(0) | 1(1.0) | 3(2.8) | ||
| N-status,n(%) | 0.209 | 0.168 | ||||
| N0 | 7(24.1) | 27(44.3) | 38(37.3) | 27(24.8) | ||
| N1 | 13(44.8) | 23(37.7) | 40(39.2) | 58(53.2) | ||
| N2 | 6(20.7) | 9(14.8) | 18(17.6) | 19(17.4) | ||
| N3 | 3(10.3) | 2(3.3) | 6(5.9) | 5(4.6) | ||
| Tumor grade | 0.066 | 0.078 | ||||
| Grade I | / | / | / | / | ||
| Grade II | 7(24.1) | 27(44.3) | 41(40.2) | 57(52.3) | ||
| Grade III | 22(75.9) | 34(55.7) | 61(59.8) | 52(47.7) | ||
| ER status | 0.050 | 0.650 | ||||
| Positive | 24(82.8) | 38(62.3) | 72(70.6) | 80(73.4) | ||
| Negative | 5(17.2) | 23(37.7) | 30(29.4) | 29(26.6) | ||
| PR status | 0.476 | 0.995 | ||||
| Positive | 24(82.8) | 38(62.3) | 59(57.8) | 63(57.8) | ||
| Negative | 5(17.2) | 23(37.7) | 43(42.2) | 46(42.2) | ||
| Her2 status | 0.883 | 0.525 | ||||
| Positive | 10(34.5) | 22(36.1) | 35(34.3) | 42(38.5) | ||
| Negative | 19(65.5) | 39(63.9) | 67(65.7) | 67(61.5) | ||
| TNBC | 0.618 | 0.428 | ||||
| yes | 2(6.9) | 15(24.6) | 16(15.7) | 13(11.9) | ||
| no | 27(93.1) | 46(75.4) | 86(84.3) | 96(88.1) | ||
| P63 | 0.967 | 0.281 | ||||
| positive | 1(3.4) | 2(3.3) | 3(2.9) | 1(0.9) | ||
| negative | 28(96.6) | 59(96.7) | ||||
| Ki-67 | 0.324 | 17(16.7) | 22(20.2) | 0.195 | ||
| < 20% | 7(24.1) | 21(34.4) | 39(38.2) | 29(26.6) | ||
| ≥ 20% | 22(75.9) | 40(65.6) | 46(45.1) | 58(53.2) | ||
T tumor stage, N nodes stage, TNBC triple negative breast cancer, Her 2 human epidermal growth factor receptor 2; * A P value < 0.05 was considered ststistically significant